MedTrace Logo

Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection

NCT00810524 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2008-12-18

No results posted yet for this study

Summary

Influence of antiviral treatment to the long term prognosis of patients with chronic HBV infection. The aim of antiviral treatment for HBV is to reduce the long term severe complications. In this study, the investigators divided patients with chronic HBV infection into two groups, which start early antiviral treatment and conventional antiviral treatment respectively. All the patients will be followed for ten years. From this study, the investigators want to find out the optimal time for patients with chronic HBV infection to start antiviral treatment.

Conditions

  • Hepatitis B, Chronic

Interventions

DRUG

lamivudine

100mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.

DRUG

Telbivudine

600mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.

DRUG

Enticavir

0.5mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2 years.

DRUG

Adefovir Dipivoxil Tablets

10mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Gao zhiliang, M. D. · Third Affiliated Hospital, Sun Yat-Sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2017-01-31
Completion
2017-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00810524 on ClinicalTrials.gov